Does lowering of blood glucose improve cardiovascular morbidity and mortality?

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 1, 2008, Pages 163-167

  Iqbal, Nayyar ^a,b,c   Rubenstein, Arthur H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS;

EID: 38749143732     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05041107     Document Type: Note

References (26)

1. Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 328: 1676-1685, 1993
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260: 2864-2871, 1988
3. Klein R, Mein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four- year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107: 237-243, 1989
4. Klein R, Klein BE, Moss S, DeMets DL: Proteinuria in diabetes. Arch Intern Med 148: 181-186, 1988
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ: Ten-year incidence of gross proteinuria in people with diabetes. Diabetes 44: 916-923, 1995
6. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22: 743-751, 1999
7. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-979, 1993
8. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
9. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
10. Ohkubo Y, Kishikawa h, Araki E, Miyata T, Isami S, Motoyoshi M, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995
11. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E, Diabetes Prevention Program Research Group: Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 30: 2453-2457, 2007
12. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288: 2579-2588, 2002
13. LeCaire T, Palta M, Zhang H, Allen C, Klein R, D'Alessio D: Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes. Am J Epidemiol 164: 143-150, 2006
14. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-Year follow-up in the White-hall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21: 360-367, 1998
15. Shankar A, Klein R, Klein BE, Moss SE: Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 166: 393-402, 2007
16. The Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294-2303, 2003
17. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321: 405-412, 2000
18. Uusitupa M, Siitonen O, Pyörälä K, Aro A, Hersio K, Penttilä I, Voutilainen E: The relationship of cardiovascular risk factors to the prevalence of coronary heart disease in newly diagnosed type 2 (non-insulin-dependent) diabetes. Diabetologia 28: 653-659, 1985
19. Reaven GM: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988
20. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 33: 81-91, 2000
21. Siperstein MD, Foster DW, Knowles HC Jr, Levine R, Madison LL, Roth J: Control of blood glucose and diabetic vascular disease. N Engl J Med 296: 1060-1063, 1977
22. Joffe HV, Parks MH, Meyer RJ, Jenkins JK, Temple R: Rosiglitazone and the FDA [Letter]. N Engl J Med 357: 1775-1776, 2007
23. Krall RL: Rosiglitazone and the FDA [Letter]. N Engl J Med 357: 1776, 2007
24. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007
25. Ness RB: Letters. New York Times Magazine September 30, 2007: 20
26. Concato, J: Letters. New York Times Magazine September 30, 2007: 20